NCT05677438 - A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions

Androgenetic Alopecia

Interventions

DRUG

CKD-498 dose#1

oral, once daily, 24 weeks

DRUG

CKD-498 dose#2

oral, once daily, 24 weeks

DRUG

CKD-498 dose#3

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#1

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#2

oral, once daily, 24 weeks

DRUG

Placebo of CKD-498 dose#3

oral, once daily, 24 weeks

Trial Locations (1)

Seoul National University Bundang Hospital, Gyeonggi-do